Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Recbio Technology Co., Ltd.
江蘇瑞科生物技術股份有限公司
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2179)

INSIDE INFORMATION ANNOUNCEMENT ANNOUNCEMENT IN RELATION TO THE REPLY FROM THE CSRC ON ISSUANCE OF DOMESTIC SHARES

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "**Company**") pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**Inside Information Provisions**") and Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

References are made to the announcements dated November 11, 2024, December 24, 2024, January 9, 2025 and February 27, 2025, and the circular dated December 5, 2024 (the "**Announcements and Circular**") in relation to, among others, details of the Company's proposed issuance of Domestic Shares and the related matters, and the acceptance by the China Securities Regulatory Commission (the "**CSRC**") of the application materials for the issuance of Domestic Shares. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcements and Circular.

The Company is pleased to announce that on July 23, 2025, the Company received the Reply of the Approval on the Registration of Shares Issued by Jiangsu Recbio Technology Co., Ltd. to the Target Subscriber (Zheng Jian Xu Ke No.[2025]1506) (《關於同意江蘇瑞科生物技術股份有限公司向特定對象發行股票註冊的批覆》(證監許可[2025]1506號)) (the "**Reply**") from the CSRC, pursuant to which the CSRC has approved the Issuance, with the details thereof set forth as follows:

1. Approval on the application for registration of Shares issued by the Company to the target subscriber.

2. The Issuance of the Company should be implemented in strict accordance with the filing documents submitted to the CSRC.

3. The Reply should be valid for a period of 12 months from the date of approval.

4. Should there be any material events occurring to the Company from the date of approval till the end of the Issuance, the Company should immediately report the same to the CSRC and take action in accordance with the relevant regulations.

As at the date of this announcement, the Issuance is subject to the satisfaction of the conditions precedent mentioned in the Announcements and Circular, and is therefore subject to uncertainties. The Company will make further announcement(s) on the progress of the Issuance in accordance with the requirements of the Inside Information Provisions and/or the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Jiangsu Recbio Technology Co., Ltd.
Dr. Liu Yong
Chairman

Jiangsu Province, the PRC, July 23, 2025

As at the date of this announcement, the Board comprises Dr. LIU Yong as the chairman of the Board and an executive Director, Mr. LI Bu, Ms. CHEN Qingqing and Dr. HONG Kunxue as executive Directors, Dr. WANG Ruwei, Dr. ZHANG Jiaxin, Dr. ZHOU Hongbin and Mr. HU Houwei as non-executive Directors, and Dr. XIA Lijun, Mr. LIANG Guodong, Professor GAO Feng and Professor YUEN Ming Fai as independent non-executive Directors.